Medical News Feed
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Esterase-metabolised narcotic analgesics. |
| Generic Name : | Remifentanil |
| Drug description : | Powder for injection in vials. |
| Presentation : | Injection, remifentanil (as hydrochloride) 1mg , 2mg , 5mg . |
| Indications : | Analgesic for use during induction and/or maintenance of general anaesthesia. |
| Adult Dosage : | Refer to Summary of Product Characteristics. |
| Child Dosage : | Under two years, not recommended; two to 12 years, refer to Summary of Product Characteristics. |
| Contra Indications : | Epidural and intrathecal use. Known hypersensitivity to any component of the preparation and other fentanyl analogues. Ultiva is contraindicated for use as the sole agent for induction of anaesthesia. |
| Special Precautions : | Ultiva should be administered only in a setting fully equipped for the monitoring and support of respiratory and cardiovascular respiratory and cardiovascular function, and by persons specifically trained in the use of anaesthetic drugs and the recognition and management of the expected adverse effects of potent opioids, including respiratory and cardiac resuscitation. Such training must include the establishment and maintenance of a patent airway and assisted ventilation. Pregnancy and lactation. Refer to Summary of Product Characteristics. |
| Interactions : | Refer to Summary of Product Characteristics. |
| Adverse Reactions : | Acute respiratory depression, bradycardia, hypotension and/or skeletal muscle rigidity. These adverse events resolve within minutes of discontinuing or decreasing the rate of remifentanil administration. Post-operative shivering, apnoea, hypoxia, constipation, sedation, nausea and vomiting have also been reported. Very rarely, allergic reactions including anaphylaxis have been reported in patients receiving remifentanil in conjunction with one or more anaesthetic agents. |
| Manufacturer : | Elan |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org